John Oyler, BeiGene CEO (Paul Yeung/Bloomberg via Getty Images)

BeiGene looks to carve out more space in the US mar­ket, set­ting up BTK drug for 2nd blood can­cer nod

BeiGene blazed the trail for a grow­ing wave of Chi­nese on­col­o­gy drugs break­ing through in the US with an ini­tial ap­proval for BTK in­hibitor Brukin­sa …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.